Players: Eurofins, Bio-Rad, QIAGEN, 10x Genomics, PacBio. Profile: cDNA sequencing technologies, products, applications, trends and competition.
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Long-Read Full-Length Complementary Deoxyribonucleic Acid (CDNA) Sequencing Global Market Report 2026" has been added to ResearchAndMarkets.com'soffering.
The global long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market is experiencing rapid growth, supported by continued advances in sequencing technologies and expanding genomics research. The market is projected to increase from $1.34 billion in 2025 to $1.59 billion in 2026, representing a compound annual growth rate (CAGR) of 18.6%. Historical growth has been driven by greater investment in genomics, increased transcriptome research, wider adoption of Pacific Biosciences and Oxford Nanopore platforms, and broader use of sequencing in gene expression studies.
Strong expansion is expected to continue through the end of the decade. The long-read full-length cDNA sequencing market is forecast to reach $3.18 billion by 2030, growing at a CAGR of 18.9%. Key growth drivers include rising demand for precision medicine, the integration of artificial intelligence-powered bioinformatics tools, increasing use of sequencing in rare disease research, expanding clinical transcriptomics, and the development of more cost-efficient long-read sequencing workflows.
Prominent market trends include growing adoption of single-cell full-length cDNA sequencing, increased demand for high-fidelity long-read platforms, and wider use of sequencing for alternative splicing detection. Research organizations are also placing greater emphasis on transcript isoform characterization and advanced library preparation kits, creating opportunities for technology developers, clinical laboratories, biotechnology businesses, and pharmaceutical companies.
The growing focus on precision medicine is expected to be a major catalyst for market development. Demand is increasing for more effective treatments for heterogeneous and therapy-resistant diseases, requiring detailed molecular information to support therapeutic decisions. Long-read full-length cDNA sequencing provides valuable insights into transcript isoforms and actionable biomarkers, helping researchers and clinicians improve targeted therapy selection.
Momentum in personalized treatment development is reflected in regulatory activity. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration authorized 16 new personalized therapies for patients with rare diseases in 2023, compared with six approvals in 2022. This increase highlights the growing importance of genomics and transcriptomics in drug development, biomarker discovery, and clinical research.
Technology providers are responding by developing high-fidelity single-molecule sequencing platforms and optimized workflows designed to improve transcript accuracy and identify complex RNA isoforms. In December 2023, Pacific Biosciences of California introduced Kinnex RNA kits to advance long-read RNA research. The kits combine high-fidelity sequencing technology with optimized library preparation workflows to generate accurate transcriptome data.
Kinnex RNA kits offer ultra-long reads spanning entire transcripts, high consensus accuracy, and compatibility with complex RNA samples. These capabilities support the identification of alternative splicing events, fusion transcripts, and previously undiscovered isoforms. Applications extend across genomics, transcriptomics, biomarker discovery, and therapeutic target identification, strengthening researchers' ability to examine RNA biology in greater detail.
Strategic partnerships are also helping expand long-read single-cell transcriptomics capabilities. In February 2026, ArgenTag entered into a partnership with Pacific Biosciences to combine highly accurate long-read sequencing platforms with single-cell analysis methods. The collaboration is intended to enable deeper cellular transcriptome profiling and improve the discovery and characterization of complex biological mechanisms. Such partnerships demonstrate the market's increasing focus on integrated sequencing and analysis solutions.
North America was the largest region in the long-read full-length cDNA sequencing market in 2025, supported by established genomics infrastructure, significant research investment, and strong adoption of advanced sequencing platforms. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market spans Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Technology: Pacific Biosciences Single-Molecule Real-Time (PacBio SMRT); Oxford Nanopore; Other Technologies
2) By Product Type: Instruments and Sequencing Platforms; Reagents and Consumables; Library Preparation Kits; Flow Cells and Chips; Data Analysis Software and Bioinformatics Tools
3) By Sample Type: Human; Animal; Plant; Microbial
4) By Application: Transcriptome Analysis; Gene Expression Studies; Alternative Splicing Detection; Fusion Gene Detection; Other Application
5) By End-Users: Academic and Research Institutes; Pharmaceutical and Biotechnology Companies; Clinical Laboratories; Other End Users
Subsegments:
1) By Pacific Biosciences Single-Molecule Real-Time (PacBio SMRT): Sequel System; Sequel II System; RS II System; High-Fidelity Sequencing Systems
2) By Oxford Nanopore: MinION Sequencing Devices; GridION Sequencing Platforms; PromethION Sequencing Platforms; Flongle Sequencing Modules
3) By Other Technologies: Synthetic Long-Read Sequencing; Linked-Read Sequencing; Single-Cell Full-Length cDNA Sequencing; Hybrid Sequencing Approaches
Time Series:Five years historic and ten years forecast.
Data:Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation:Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
| Report Attribute |
Details |
|---|---|
| No. of Pages |
250 |
| Forecast Period |
2026 - 2030 |
| Estimated Market Value (USD) in 2026 |
$1.59 Billion |
| Forecasted Market Value (USD) by 2030 |
$3.18 Billion |
| Compound Annual Growth Rate |
18.9% |
| Regions Covered |
Global |
Companies Featured
The companies featured in this Long-Read Full-Length Complementary Deoxyribonucleic Acid (CDNA) Sequencing market report include:
-
Eurofins Scientific SE
-
Bio-Rad Laboratories Inc.
-
QIAGEN N.V.
-
10x Genomics Inc.
-
Azenta Life Sciences Inc.
-
BGI Genomics Co. Ltd.
-
Novogene Co. Ltd.
-
Takara Bio Inc.
-
Oxford Nanopore Technologies plc
-
Pacific Biosciences of California Inc.
-
New England Biolabs Inc.
-
Macrogen Inc.
-
DNAnexus Inc.
-
Zymo Research Corporation
-
CD Genomics Inc.
-
BaseClear B.V.
-
Microsynth AG
-
Creative Biogene Inc.
-
Nucleome Informatics Inc.
-
Operify Tech Pvt. Ltd.
-
Signios Bio Inc.
For more information about this report visit https://www.researchandmarkets.com/r/1zw6uk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
